Latest News Ocular Therapeutix' Antony Mattessich to Assume CEO Role; Amar Sawhney Becomes Board's Exec Chairman By Staff Wednesday, June 28, 2017 12:21 AM BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, announced that in line with Ocular’s strategic plan and growth objectives, Antony Mattessich will succeed Dr. Amar Sawhney as CEO, on or before Sept. 30, 2017.Until that time, Dr. Sawhney will continue to serve as CEO and chairman of the board of directors, and will then transition to an executive chairman role. As executive chairman, Dr. Sawhney will continue to devote substantial business time to Ocular Therapeutix. Mattessich has also been elected to the company’s board, effective immediately.“I am tremendously excited to have Antony Mattessich join the Ocular Therapeutix team. Antony’s strong track record of commercial, operational and business development experience will build upon the research and development foundation established through the efforts of Ocular Therapeutix's founding team,” said Sawhney, president, CEO and chairman.“Antony has over 25 years of experience building, managing and growing global pharmaceutical organizations to large, successful companies and brands. In my capacity as executive chairman, I will continue to provide Ocular Therapeutix with my input and expertise to facilitate continuity and a smooth transition as we head to this exciting new phase for the company,” Dr. Sawhney. Added.Mattessich has held leadership roles for a number of global pharmaceutical companies across the U.S., Europe and Asia, including Novartis, Bristol Meyers Squibb and Merck & Co. Most recently, Mattessich was the managing director of Mundipharma, a large privately-owned company. He holds a Master’s Degree in International Affairs from Columbia University and a Bachelor of Arts from University of California, Berkeley.To facilitate Mattessich’s election to the board, James Garvey has resigned from the board. Dr. Sawhney added, “As one of the earliest venture investors, we thank Jim for his many years of invaluable service on the board."